Bone morphogenic protein-7 and the kidney: current concepts and open questions.

version from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients. ATC Seattle 2005 28. Saurina A, Campistol JM, Piera C et al. Conversion form calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular hemodynamics and proteinuria. Nephrol Dial Transpl; in press 29. Fervenza FC, Fitzpatrick PM, Mertz J et al. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic algomerulopahties. Nephol Dial Transplant 2004; 19: 1288–1292 30. Marti HP, Frey F. Nephrotoxicity of rapamycin: an emerging problem in clinical medicine. Nephrol Dial Transplant 2005; 20: 13–15 31. Weir MR, Ward MT, Blahut SA et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59: 1567–1573 32. Van Gelder T, ter Meulen CG, Hené R, Weimar W, Hoitsma A. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003; 75: 788–791 33. Anglicheau D, Le Corre D, Lechaton S et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant 2005; 5: 595–603 34. Morelon E, Stern M, Israel-Biet D et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001; 72: 787–790 35. Mahé E, Morelon E, Lechaton S et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005; 79: 476–482 36. Dittrich E, Schmaldienst S, Soleiman A et al. Rapamycinassociated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 2004; 17: 215–220